<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00725127</url>
  </required_header>
  <id_info>
    <org_study_id>CARING-2008/1</org_study_id>
    <secondary_id>2008-002669-30</secondary_id>
    <nct_id>NCT00725127</nct_id>
  </id_info>
  <brief_title>Chronotherapy With Low-dose Aspirin for Primary Prevention</brief_title>
  <acronym>CARING</acronym>
  <official_title>Chronotherapy With Low-dose Aspirin for Primary Prevention of Cardiovascular Events in Subjects With Impaired Fasting Glucose or Diabetes (CARING Study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vigo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Vigo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brief summary:

      Aspirin (ASA) has been shown to provide marked benefits in primary and secondary prevention
      of cardiovascular events. Substantial evidence suggests that low-dose ASA therapy should also
      be used as a primary prevention strategy in men and women with diabetes who are at high
      cardiovascular risk. On the other hand, there is current evidence on the potential benefits
      of low-dose ASA therapy in subjects with impaired fasting glucose, including those with
      metabolic syndrome. Most important, previous laboratory animal and clinical trial research
      convincingly demonstrates administration time-dependent (with reference to circadian rhythms)
      effects of ASA. Thus, the effects of ASA upon lipoperoxides, b-adrenergic receptors, and
      blood pressure (BP) in clinically healthy subjects depend on the circadian timing of ASA
      administration. The administration-time-dependent influence of ASA on BP was previously
      demonstrated in a randomized trial on healthy women and other independent double-blind,
      randomized, placebo-controlled clinical trials conducted, first, on clinically healthy
      subjects, a second one on normotensive and hypertensive subjects, a third one on pregnant
      women at high risk for preeclampsia and a fourth one in previously untreated patients with
      mild hypertension. The findings of these BP studies are consistent; BP-lowering effect of
      low-dose ASA is achieved when administered at bedtime but not upon awakening.

      In keeping with the chronopharmacological effects of ASA and the previous findings suggesting
      that ASA at low dose may exert a potential beneficial effect on BP, endothelium function and
      cardiovascular function, this prospective, randomized, parallel-arm study will investigate
      the potential influence of ASA on the primary prevention of cardiovascular, cerebrovascular
      and renal events in subjects with either impaired fasting glucose (≥ 100 mg/dl) or previous
      diagnosis of type 2 diabetes mellitus, who will receive low-dose ASA (100 mg/day) at
      different circadian times (upon awakening or at bedtime) in relation to their rest-activity
      cycle.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effects of awakening vs. bedtime 100 mg/day ASA administration in subjects with impaired fasting glucose or type 2 diabetes on primary prevention of cardiovascular, cerebrovascular and renal fatal, and non-fatal events.</measure>
    <time_frame>Five years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of awakening vs. bedtime 100 mg/day ASA administration on primary prevention of cardiovascular fatal and non-fatal events (including cardiovascular death, myocardial infarction, angina pectoris, and coronary revascularization).</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of awakening vs. bedtime 100 mg/day ASA administration on primary prevention of cerebrovascular fatal and non-fatal events (including hemorrhagic stroke, ischemic stroke, and transient ischemic attack).</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of awakening vs. bedtime 100 mg/day ASA administration on primary prevention of chronic kidney disease and/or congestive heart failure, and/or peripheral artery disease.</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To demonstrate that 100 mg/day ASA at bedtime offers a similar safety profile than 100 mg/day ASA upon awakening</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To demonstrate that compliance with 100 mg/day ASA at bedtime is similar to that with 100 mg/day ASA upon awakening.</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate, for all previous objectives, potential gender differences in the benefits of low-dose ASA for primary prevention.</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate, for all previous objectives, potential differences in the benefits of low-dose ASA for primary prevention between patients with and without diabetes.</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate, for all previous objectives, potential differences in the benefits of low-dose ASA for primary prevention between subjects with and without metabolic syndrome.</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3200</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg/day ASA upon awakening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg/day ASA at bedtime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>100 mg/day upon awakening for five years</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Aspirin on awakening</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>100 mg/day at bedtime for five years</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Aspirin at bedtime</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects ≥ 50 years of age.

          -  Impaired fasting glucose (≥ 100 and &lt; 126 mg/dl) in the last available blood test
             prior (≤ 3 months) to randomization, or diagnosis of type 2 diabetes prior to
             randomization.

          -  All subjects must have at randomization a conventional clinic systolic/diastolic BP &lt;
             160/100 mmHg.

          -  Informed consent to participate in the study prior to any study procedures.

        Exclusion Criteria:

          -  Known or suspected contraindications, including history of allergy to ASA.

          -  Uncontrolled essential hypertension of Grade 2-3, i.e., systolic BP ≥ 160 mmHg and/or
             diastolic BP ≥ 100 mmHg before randomization.

          -  Evidence of a secondary form of hypertension, to include coarctation of the aorta,
             hyperaldosteronism, renal artery stenosis, or pheochromocytoma.

          -  Known Keith-Wagener grade III or IV hypertensive retinopathy.

          -  History of hypertensive encephalopathy, cerebrovascular event, transient ischemic
             cerebral attack, or myocardial infarction prior to randomization.

          -  Type 1 diabetes mellitus.

          -  History of heart failure.

          -  Second or third degree heart block without a pacemaker.

          -  Concomitant unstable angina pectoris.

          -  Concomitant potentially life threatening arrhythmia or symptomatic arrhythmia.

          -  Clinically significant valvular heart disease.

          -  Evidence of hepatic disease as determined by one of the following: ALT or AST values &gt;
             2 x UNL known before randomization, a history of hepatic encephalopathy, history of
             esophageal varices, or history of portocaval shunt.

          -  Diagnosis of chronic kidney disease prior to randomization.

          -  History of malignancy including leukemia and lymphoma (but not basal cell skin
             cancer), or any other severe, life-threatening disease within the past five years.

          -  Any previous history of a systemic autoimmune disease.

          -  History of drug or alcohol abuse within the last two years.

          -  Use of any disallowed concomitant medication.

          -  Inability to communicate and comply with all study requirements.

          -  Persons directly involved in the execution of this protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramon C Hermida, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Vigo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ramon C Hermida, PhD</last_name>
    <phone>34986812148</phone>
    <email>rhermida@uvigo.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diana E Ayala, MD, PhD</last_name>
    <phone>34986812148</phone>
    <email>dianaelva@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CS Friol</name>
      <address>
        <city>Friol</city>
        <state>Lugo</state>
        <zip>27220</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Gomez, MD</last_name>
      <phone>34639512093</phone>
      <email>Esther.Gomez.Sal@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Esther Gomez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Baiona</name>
      <address>
        <city>Baiona</city>
        <state>Pontevedra</state>
        <zip>36300</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco J Iglesias, MD</last_name>
      <phone>34986357239</phone>
      <email>FranciscoJavier.Iglesias.Mato@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Francisco J Iglesias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Bueu</name>
      <address>
        <city>Bueu</city>
        <state>Pontevedra</state>
        <zip>36930</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel A Aboal, MD</last_name>
      <phone>34986323313</phone>
      <email>miguel.angel.aboal.beato@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Miguel A Aboal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS A Estrada</name>
      <address>
        <city>La Estrada</city>
        <state>Pontevedra</state>
        <zip>26680</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Meijide, MD</last_name>
      <phone>34986573459</phone>
      <email>Luis.Meijide.Calvo@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Luis Meijide, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariana Carbon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria C Garcia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Romero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria P Brea</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS A Guarda</name>
      <address>
        <city>La Guardia</city>
        <state>Pontevedra</state>
        <zip>36780</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan J Crespo, MD</last_name>
      <phone>34986614450</phone>
      <email>JuanJose.Crespo.Sabaris@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Juan J Crespo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raquel Fernandez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen M Fernandez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amelia Ferreras, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel F Quintans, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier Rodriguez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pilar Rua</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurelio Alvarez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asuncion Cadilla</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Outeiro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Soto-Davila</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Valmiñor</name>
      <address>
        <city>Nigran</city>
        <state>Pontevedra</state>
        <zip>36250</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana Hernaiz, MD</last_name>
      <phone>34655391498</phone>
      <email>Susana.Hernaiz.Valero@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Susana Hernaiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Panxón</name>
      <address>
        <city>Nigrán</city>
        <state>Pontevedra</state>
        <zip>36340</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose L Salgado, MD</last_name>
      <phone>34986368615</phone>
      <email>joseluis.salgado.conde@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Jose L Salgado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esperanza Parrado</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alfredo Pereira</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Tomiño</name>
      <address>
        <city>Tomiño</city>
        <state>Pontevedra</state>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evangelina Filloy, MD</last_name>
      <phone>34-986-623411</phone>
      <email>evangelina.filloy.miguez@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Evangelina Filloy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adolfo T Perez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nieves Turienzo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dolores Cardalda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose C Varela</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisca Vazquez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bioengineering &amp; Chronobilogy Labs., University of Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon C Hermida, PhD</last_name>
      <phone>34986812148</phone>
      <email>rhermida@uvigo.es</email>
    </contact>
    <contact_backup>
      <last_name>Diana E Ayala, MD, PhD</last_name>
      <phone>34986812148</phone>
      <email>dianaelva@uvigo.es</email>
    </contact_backup>
    <investigator>
      <last_name>Ramon C Hermida, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana E Ayala, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Artemio Mojon, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose R Fernandez, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ignacio Alonso, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria J Fontao</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rita Soler</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susana Serrano</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Calle Cuba</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36202</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felisa Dominguez, MD</last_name>
      <phone>34986416226</phone>
      <email>fdominguez@meditex.es</email>
    </contact>
    <investigator>
      <last_name>Felisa Dominguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS A Doblada</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36205</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Rios, MD</last_name>
      <phone>34986275121</phone>
      <email>teresa.rios.rey@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Teresa Rios, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Coia</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36209</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peregrina Eiroa, MD</last_name>
      <phone>34986209282</phone>
      <email>pereeiroa@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Peregrina Eiroa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jesus C Nieto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Sardoma</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36214</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Dominguez, MD, PhD</last_name>
      <phone>34986416324</phone>
      <email>Manuel.Dominguez.Sardina@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Manuel Dominguez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Teis</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36216</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro A Callejas, MD</last_name>
      <phone>34986374229</phone>
      <email>PedroAntonio.Callejas.Cabanillas@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Pedro A Callejas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Vilaboa</name>
      <address>
        <city>Vilaboa</city>
        <state>Pontevedra</state>
        <zip>36141</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia M Gomara, MD</last_name>
      <phone>34986679229</phone>
      <email>SoniaMaria.Gomara.Villabona@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Sonia M Gomara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julio J Alvarez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margarita Estevez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria C Ferreira</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS San Roque</name>
      <address>
        <city>Vilagarcía De Arousa</city>
        <state>Pontevedra</state>
        <zip>36600</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Envira Sineiro, MD</last_name>
      <phone>34986507448</phone>
      <email>Elvira.Sineiro.Galinanes@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Elvira Sineiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margarita Alvariño</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis M Fontenla</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margarita Fraga, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Llovo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rita Martinez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Santiago Santidrian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Fingoi</name>
      <address>
        <city>Lugo</city>
        <zip>27002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Castiñeira, MD</last_name>
      <phone>34982251035</phone>
      <email>Carmen.Castineira.Perez@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Carmen Castiñeira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria C Aguado</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Costa</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Domingo D Garcia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernardino Pardo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrique J Vazquez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Ourense</name>
      <address>
        <city>Orense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Otero, MD, PhD</last_name>
      <phone>34988385625</phone>
      <email>Alfonso.Santiago.Otero.Gonzalez@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Alfonso Otero, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Lerez</name>
      <address>
        <city>Pontevedra</city>
        <zip>36156</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Moya, MD</last_name>
      <phone>34986871496</phone>
      <email>ana.moya.alvarez@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Ana Moya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andres Ruiz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurelia Constenla</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria I Franco</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.hygia.es</url>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2008</study_first_submitted>
  <study_first_submitted_qc>July 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2008</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vigo</investigator_affiliation>
    <investigator_full_name>Ramon C. Hermida</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Aspirin</keyword>
  <keyword>Chronotherapy</keyword>
  <keyword>Primary prevention</keyword>
  <keyword>Impaired fasting glucose</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Total mortality</keyword>
  <keyword>Myocardial infarction</keyword>
  <keyword>Stroke</keyword>
  <keyword>Angina pectoris</keyword>
  <keyword>Chronic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

